We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




Calprotectin Fecal Assay Adapted for Serum Samples

By LabMedica International staff writers
Posted on 16 Feb 2022
Print article
Image: The LIAISON XL is a fully automated chemiluminescence analyzer, performing complete sample processing as well as measurement and evaluation (Photo courtesy of Medical Laboratory Observer)
Image: The LIAISON XL is a fully automated chemiluminescence analyzer, performing complete sample processing as well as measurement and evaluation (Photo courtesy of Medical Laboratory Observer)

Calprotectin is a calcium-binding protein that belongs to the S100 family, which is present in immune cells such as macrophages, monocytes, and neutrophils and in epithelial and endothelial cells. Increased serum and plasma calprotectin concentrations have been found in chronic inflammatory rheumatic disorders.

Calprotectin can be measured in serum, plasma, and feces. Increased serum and plasma calprotectin concentrations have been found in chronic inflammatory rheumatic disorders such as juvenile chronic arthritis, rheumatoid arthritis (RA), Behçet disease, and Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Clinical Biochemists at the Hospital Clinic of Barcelona (Barcelona, Spain) evaluated the association between calprotectin serum levels and disease activity in RA, they included 49 consecutive patients with RA (fulfilling ACR/EULAR 2010 classification criteria) evaluated during the course of 2019 in the outpatient clinic of Rheumatology of their hospital, with different degrees of disease activity. Serum calprotectin concentrations in 26 active and 23 remission RA patients were compared.

The scientists used the LIAISON® XL (DiaSorin, Saluggia, Italy) for the quantitation of serum calprotectin. This is a fully automated analyzer using chemiluminescence technology with magnetic microparticles that performs complete sample processing, as well as measurement and evaluation being able to analyze up to 180 tests per hour. Forty-two serum samples in the range from 0.5 to 10 µg/mL were analyzed using DiaSorin Liaison Calprotectin assay and CalproLab ELISA kit (Svar, Malmö, Sweden), a validated assay for testing plasma/serum samples.

The investigators reported that the intra-day and inter-day analytical imprecision CVs ranged from 2.9% to 4.0% and 2.7% to 10.4%, respectively. Correlation between measured and expected values was high indicating good linearity. The Wilcoxon signed-rank test showed that serum and plasma matched samples presented statistically significant differences, where the highest concentrations of calprotectin observed in serum samples. Significantly higher serum calprotectin levels were found in RA patients with active disease when compared to patients with low disease activity or in clinical remission (mean ± SD) [(3.35 μg/mL ± 1.55) versus (1.63 μg/mL ± 0.52), and these levels correlated well with all disease activity indices.

The authors concluded that the DiaSorin Liaison fecal Calprotectin assay adapted for serum samples showed adequate technical performances and a good agreement with CalproLab ELISA kit, furthermore, the clinical performances are similar to other assays. They have estimated reference limits in patients with RA and observed a good correlation between serum calprotectin and RA activity, similar to those reported previously. The study was published on February 5 2022, in the Journal of Clinical Laboratory Analysis.

Related Links:
Hospital Clinic of Barcelona 
DiaSorin 
Svar 

 

 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.